S

SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600

Watchlist Manager
SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
Watchlist
Price: 18.72 HKD
Market Cap: 11.8B HKD

Net Margin
SciClone Pharmaceuticals (Holdings) Ltd

35.6%
Current
36%
Average
4.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
35.6%
=
Net Income
1.1B
/
Revenue
3.2B

Net Margin Across Competitors

No Stocks Found

SciClone Pharmaceuticals (Holdings) Ltd
Glance View

Market Cap
11.3B HKD
Industry
Pharmaceuticals

SciClone Pharmaceuticals (Holdings) Ltd. operates at the fascinating intersection of biotechnology and pharmaceuticals, delivering innovative solutions in the healthcare sector. With roots firmly planted in the bustling life sciences landscape of China, SciClone specializes in the development and commercialization of novel medicines that address critical health concerns, particularly in oncology, infectious diseases, and cardiovascular conditions. By leveraging a strategic blend of in-house research and development, coupled with partnerships with global biotech firms, SciClone is able to bring cutting-edge therapies to market. This blend of innovation and collaboration fuels the company’s pipeline, allowing it to introduce new medical solutions to meet the ever-growing demand for advanced healthcare in a rapidly aging population. The financial engine of SciClone revolves around its adept management of significant partnerships and distribution networks, ensuring their pharmaceutical products reach a broad base of healthcare providers and patients. Their business model is anchored in acquiring licensing rights for promising drug candidates, which they then shepherd through clinical trials and regulatory approvals. Once approved, these drugs are marketed through SciClone’s robust sales channels. This model not only diversifies their revenue streams but also mitigates risk by relying on a portfolio of products rather than a single offering. Importantly, by focusing on high-margin specialty pharmaceuticals, SciClone has positioned itself as a nimble player in the pharmaceutical landscape, with an eye toward sustainable growth and expansion in emerging markets.

Intrinsic Value
Not Available
S
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
35.6%
=
Net Income
1.1B
/
Revenue
3.2B
What is the Net Margin of SciClone Pharmaceuticals (Holdings) Ltd?

Based on SciClone Pharmaceuticals (Holdings) Ltd's most recent financial statements, the company has Net Margin of 35.6%.

Back to Top